NASDAQ: SPRY
Ars Pharmaceuticals Inc Stock

$17.56-0.34 (-1.9%)
Updated Jul 15, 2025
SPRY Price
$17.56
Fair Value Price
-$1.12
Market Cap
$1.72B
52 Week Low
$8.91
52 Week High
$18.90
P/E
-103.29x
P/B
7.53x
P/S
12.7x
PEG
N/A
Dividend Yield
N/A
Revenue
$97.12M
Earnings
-$15.65M
Gross Margin
97.9%
Operating Margin
-15.82%
Profit Margin
-16.1%
Debt to Equity
0.43
Operating Cash Flow
-$20M
Beta
1.01
Next Earnings
Aug 6, 2025
Ex-Dividend
N/A
Next Dividend
N/A

SPRY Overview

Silverback Therapeutics Incoporated is a clinical-stage biopharmaceutical company that develops ImmunoTAC therapies targeting previously inaccessible disease pathways. Its tissue-targeted therapeutics treat chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B. Silverback Therapeutics was incorporated in 2016 and is headquartered in Seattle, WA.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine SPRY's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More

Zen Rating Component Grades

C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Biotech

Industry Rating
F
SPRY
Ranked
#201 of 473

Top Ranked Stocks in Industry

View Top Biotech Stocks

Be the first to know about important SPRY news, forecast changes, insider trades & much more!

SPRY News

Overview

Due Diligence Score

Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SPRY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

SPRY ($17.56) is overvalued by 1,674.79% relative to our estimate of its Fair Value price of -$1.12 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SPRY ($17.56) is not significantly undervalued (1,674.79%) relative to our estimate of its Fair Value price of -$1.12 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SPRY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SPRY due diligence checks available for Premium users.

Valuation

SPRY fair value

Fair Value of SPRY stock based on Discounted Cash Flow (DCF)

Price
$17.56
Fair Value
-$1.12
Undervalued by
1,674.79%
SPRY ($17.56) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SPRY ($17.56) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SPRY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

SPRY price to earnings (PE)

For valuing profitable companies with steady earnings

Company
-103.29x
Industry
-153.81x
Market
31.02x

SPRY price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
7.53x
Industry
4.57x
SPRY is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation

SPRY's financial health

Profit margin

Revenue
$8.0M
Net Income
-$33.9M
Profit Margin
-425.7%
SPRY's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SPRY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$327.3M
Liabilities
$98.3M
Debt to equity
0.43
SPRY's short-term assets ($303.86M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SPRY's short-term assets ($303.86M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SPRY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$40.7M
Investing
$29.1M
Financing
$725.0k
SPRY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

SPRY vs Biotech Stocks

TickerZen RatingMarket Cap1d %P/EP/B
SPRYC$1.72B-1.90%-103.29x7.53x
TARSC$1.70B-2.29%-14.92x4.98x
IMCRB$1.77B-0.42%-81.74x4.67x
OCULF$1.77B-1.60%-9.73x6.64x
ADPTC$1.68B-4.24%-11.64x8.82x

Ars Pharmaceuticals Stock FAQ

What is Ars Pharmaceuticals's quote symbol?

(NASDAQ: SPRY) Ars Pharmaceuticals trades on the NASDAQ under the ticker symbol SPRY. Ars Pharmaceuticals stock quotes can also be displayed as NASDAQ: SPRY.

If you're new to stock investing, here's how to buy Ars Pharmaceuticals stock.

What is the 52 week high and low for Ars Pharmaceuticals (NASDAQ: SPRY)?

(NASDAQ: SPRY) Ars Pharmaceuticals's 52-week high was $18.90, and its 52-week low was $8.91. It is currently -7.09% from its 52-week high and 97.19% from its 52-week low.

How much is Ars Pharmaceuticals stock worth today?

(NASDAQ: SPRY) Ars Pharmaceuticals currently has 98,213,561 outstanding shares. With Ars Pharmaceuticals stock trading at $17.56 per share, the total value of Ars Pharmaceuticals stock (market capitalization) is $1.72B.

Ars Pharmaceuticals stock was originally listed at a price of $25.00 in Dec 4, 2020. If you had invested in Ars Pharmaceuticals stock at $25.00, your return over the last 4 years would have been -29.76%, for an annualized return of -8.45% (not including any dividends or dividend reinvestments).

How much is Ars Pharmaceuticals's stock price per share?

(NASDAQ: SPRY) Ars Pharmaceuticals stock price per share is $17.56 today (as of Jul 15, 2025).

What is Ars Pharmaceuticals's Market Cap?

(NASDAQ: SPRY) Ars Pharmaceuticals's market cap is $1.72B, as of Jul 16, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Ars Pharmaceuticals's market cap is calculated by multiplying SPRY's current stock price of $17.56 by SPRY's total outstanding shares of 98,213,561.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.